- Main
Early antibody treatment, inflammation, and risk of post-COVID conditions
- Gebo, Kelly A;
- Heath, Sonya L;
- Fukuta, Yuriko;
- Zhu, Xianming;
- Baksh, Sheriza;
- Abraham, Allison G;
- Habtehyimer, Feben;
- Shade, David;
- Ruff, Jessica;
- Ram, Malathi;
- Laeyendecker, Oliver;
- Fernandez, Reinaldo E;
- Patel, Eshan U;
- Baker, Owen R;
- Shoham, Shmuel;
- Cachay, Edward R;
- Currier, Judith S;
- Gerber, Jonathan M;
- Meisenberg, Barry;
- Forthal, Donald N;
- Hammitt, Laura L;
- Huaman, Moises A;
- Levine, Adam;
- Mosnaim, Giselle S;
- Patel, Bela;
- Paxton, James H;
- Raval, Jay S;
- Sutcliffe, Catherine G;
- Anjan, Shweta;
- Gniadek, Thomas;
- Kassaye, Seble;
- Blair, Janis E;
- Lane, Karen;
- McBee, Nichol A;
- Gawad, Amy L;
- Das, Piyali;
- Klein, Sabra L;
- Pekosz, Andrew;
- Bloch, Evan M;
- Hanley, Daniel;
- Casadevall, Arturo;
- Tobian, Aaron AR;
- Sullivan, David J;
- Consortium, on behalf of the CSSC-004
- Editor(s): Mahalingam, Suresh
Published Web Location
https://doi.org/10.1128/mbio.00618-23Abstract
IMPORTANCE: Approximately 20% of individuals infected with SARS-CoV-2 experienced long-term health effects, as defined PCC. However, it is unknown if there are any early biomarkers associated with PCC or whether early intervention treatments may decrease the risk of PCC. In a secondary analysis of a randomized clinical trial, this study demonstrates that among outpatients with SARS-CoV-2, increased IL-6 at time of infection is associated with increased odds of PCC. In addition, among individuals treated early, within 5 days of symptom onset, with COVID-19 convalescent plasma, there was a trend for decreased odds of PCC after adjusting for other demographic and clinical characteristics. Future treatment studies should be considered to evaluate the effect of early treatment and anti-IL-6 therapies on PCC development.
Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.